IMA is pushing on continuous manufacturing in the pharmaceutical production within the new Innovation Hub.
IMA has presented on Achema the new Process Innovation Hub, a corner dedicated to novel process technologies: Continuous Pharmaceutical offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals, where the synthesis of the active ingredient and the final dosage form are integrated into a seamless process.
This novel method allows “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs. Share a new way to design freeze dryers and innovative processes with regard to accelerating freeze-drying. Ice-fog nucleation and spray freeze dryers are on the go.
Last year IMA formed a strategic partnerchip with Continuus Pharmaceuticals. The company is a spin-out of the Novartis-MIT Center for Continuous Manufacturing, a ten-year joint research endeavor at MIT that started in 2007 to develop novel continuous flow manufacturing technologies for small-molecule pharmaceuticals. The project was successful, and led to the first pilot plant able to produce finished drug tablets from raw chemical ingredients through a fully automated, integrated continuous process (i.e. Integrated Continuous Manufacturing, ICM). ICM represents the ultimate state of lean manufacturing for pharmaceuticals. Consequently, Novartis has initiated the technology transfer to its novel “Technikum” Plant in Basel, Switzerland.
The company also has shown the new Patvis Apa system which is a process analytical technology visual inspection system for monitoring, understanding and optimization of fluid bed pharmaceutical production processes. It is portable and can be easily integrated to existing viewing ports for in-line inspection or used as a standalone device for at-line or off-line inspection, the company says.